AI Consensus Investment Thesis
Recursion Pharmaceuticals (RXRX) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Hold & Monitor
Model signals are balanced; wait for clearer evidence.
1-Year
NEUTRAL$3.58
+7.0%5-Year
NEUTRAL$9.08
+171.0%Latest flagship insight
How Proprietary Biological Token Scarcity Is Redefining High-Performance Computing Valuations
A sharp divergence exists between traditional clinical-stage biotechnology valuations and the asset's emerging role as a sovereign biological data infrastructure monopoly. While high operational cash burn remains a primary near-term risk, geopolitical reshoring mandates and proprietary phenomic datasets drive long-term platform consensus.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The asset represents a high-beta platform play positioned at the intersection of generative biology and high-performance computing. While the current macro regimemacro regimeA persistent combination of growth, inflation, policy, and liquidity conditions affecting asset prices.View full glossary entry of restrictive monetary policy and high capital costs penalizes its substantial operational cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry, the long-term investment thesis hinges on the transition from a speculative clinical-stage biotech to an indispensable biological data utility. The integration of advanced chemistry engines and automated wet-lab infrastructure establishes a highly defensible, sovereign data moatdata moatA durable competitive advantage created by proprietary, difficult-to-replicate, or continuously improving data.View full glossary entry that is increasingly valuable as frontier AI models face open-source training token exhaustion. This unique positioning allows the company to act as a critical infrastructure provider rather than a traditional binary drug developer.
Key insights
- High operational cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry of approximately four hundred million dollars annually requires disciplined capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry and creates near-term refinancing risks.
- Geopolitical reshoringreshoringMoving production or supply operations back to the domestic market from overseas locations.View full glossary entry driven by legislative mandates funnels domestic pharmaceutical partnerships toward secure, US-based automated laboratories.
- Proprietary multi-omic and phenomic datasets provide a structural competitive advantage over pure-software computational biology competitors.
- Strategic compute subsidies and deep hardware partnerships insulate the platform from escalating infrastructure and silicon costs.
- The primary risk remains the high historical attrition rate of clinical translation from in-silico models to human biology.
- Long-term valuation depends on transitioning from lumpy milestone payments to high-margin, recurring platform licensing agreements.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative views the asset as a broken, highly speculative pandemic-era darling that has failed to deliver on its promise of revolutionizing medicine. The crowd and sell-side analysts are heavily anchored to the company's massive annual cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry and recent revenue misses, treating the stock as a binary clinical lottery ticket. The prevailing consensus trade is to short or avoid the asset, focusing strictly on near-term clinical trial risks and the lack of immediate commercial revenue, while dismissing the underlying artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry and supercomputing capabilities as overhyped buzzwords that cannot bypass traditional FDA clinical trial bottlenecks.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in a profound structural categorization error: the market values the asset as a traditional clinical-stage biotechnology firm, assigning zero value to its core data infrastructure. While the crowd obsessively focuses on operating losses and clinical trial attrition, the variant perceptionvariant perceptionAn investment view that differs from market consensus and assumes future outcomes will be better or worse than widely expected.View full glossary entry recognizes the asset as a sovereign biological data monopoly. In an era where frontier artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry models are rapidly exhausting publicly available training data, the company's massive, proprietary, machine-readable phenomic and transcriptomic datasets represent a critical geopolitical and commercial chokepoint. The asset's true floor value is anchored by this irreplaceable data reservoir and its automated wet-lab infrastructure, which legacy pharmaceutical giants and technology hyperscalershyperscalersVery large cloud or internet-platform operators that run computing infrastructure at global scale.View full glossary entry will inevitably be forced to license to survive their own research failures and supply-chain decoupling.
Repricing Catalyst
What could make the market recognize and close that gap? The valuation gapvaluation gapThe difference between a market price and an analyst's estimate of intrinsic value.View full glossary entry is expected to close upon the execution of a transformative, multi-billion-dollar non-dilutive platform licensing or data-access agreement with a top-tier global pharmaceutical giant or a major technology hyperscaler. This catalyst, anticipated within the next 18 to 24 months, will be driven by acute proprietary data starvation across the industry and patent cliffs forcing legacy firms to outsource early-stage discovery. Such an event will mathematically re-rate the company from a speculative clinical biotech to an entrenched, high-margin biological utility, making the platform's commercial viability impossible for the market to ignore.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Reversal
While there is strong consensus regarding the high expected volatility of the asset due to its rapid cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry, reports diverge on the current cycle position. Some perspectives view the asset as undergoing a structural reversal or capitulation, while others suggest it has entered a stabilization phase supported by strategic partnerships and defensive cost-cutting measures.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop presents a highly bifurcated setup. The Federal Reserve's restrictive monetary policy, characterized by structurally higher interest rates and tight liquidity, acts as a severe headwind that aggressively penalizes long-duration, cash-burning assets. However, this monetary pressure is offset by a powerful geopolitical tailwind. The implementation of the BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry and accelerating supply-chain decoupling force Western pharmaceutical companies to abandon Chinese research organizations. This regulatory shift funnels capital directly toward secure, US-domiciled automated discovery platforms, partially mitigating the hostile macroeconomic environment.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports centers on the valuation framework and the competitive durability of the company's supercomputing infrastructure. Some perspectives argue that the proprietary dataset and automated wet labs represent an unassailable, sovereign monopoly that will inevitably command premium licensing fees. Conversely, more skeptical views suggest that the platform's hardware advantage is rapidly depreciating and easily replicated by mega-cap pharmaceutical companies deploying their own massive GPU clusters. Additionally, reports clash on the timing and severity of the impending dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry wall, with estimates of the cash runway varying based on assumed partnership milestone inflows.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Proprietary Biological Data Moatdata moatA durable competitive advantage created by proprietary, difficult-to-replicate, or continuously improving data.View full glossary entry | Competitive Positioning | +45% | +35% | The company's massive, standardized phenomic and transcriptomic dataset serves as a critical competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry. As artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry models exhaust public training tokens, high-fidelity biological data becomes a scarce, non-replicable asset. This positions the platform as an essential toll bridgetoll bridgeToll bridge describes a business model that earns recurring fees by controlling access to an essential network, platform, or transaction pathway.View full glossary entry for pharmaceutical and technology giants seeking to train generative biology models, driving intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry appreciation independent of near-term clinical trial outcomes. |
| BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry Supply Chain Reshoringsupply chain reshoringSupply chain reshoring is the relocation of production or sourcing closer to domestic markets to improve resilience, control, or policy alignment.View full glossary entry | Regulatory | +30% | +25% | Geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry and legislative mandates like the BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry are forcing Western pharmaceutical companies to decouple from Chinese research organizations. As a secure, US-domiciled automated data-generation platform, the company is uniquely positioned to capture this redirected capital, transforming its facilities into a politically protected national bio-infrastructure utilityinfrastructure utilityAn essential network or physical service with durable demand and utility-like economic characteristics.View full glossary entry. |
| Non-Dilutive Strategic Partnerships | Sector And Industry | +25% | +30% | Established collaborations with legacy pharmaceutical giants and technology leaders provide critical non-dilutive milestone payments and capital injections. These partnerships validate the phenotypic screening platform and help offset the company's massive research and development expenditures, protecting existing equity holders from severe dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry during restrictive monetary cycles. |
| Exscientia Integration Synergies | Operational Efficiency | +15% | +20% | The integration of Exscientia's generative chemistry engine with the company's biological operating system completes a vertical discovery stack. This synergy compresses the timeline from target identification to small molecule design, significantly improving operational efficiencyoperational efficiencyThe ability to produce an intended output or service with minimal waste, delay, or cost.View full glossary entry and reducing the capital required per drug candidate over the forecast horizon. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| High Operational Cash Burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry | Macroeconomic And Macrofinancial | -40% | -15% | The company's massive annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry deficit, driven by high supercomputing and clinical trial expenditures, acts as a severe gravitational pull on valuation. In a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry with high interest rates, long-duration, unprofitable assets face severe duration penalties and multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry as capital remains expensive. |
| Impending Shareholder Dilution | Capital Allocation | -30% | -10% | With a finite cash runway, the company faces a structural refinancing wall within the medium term. If partnership milestones are delayed, management will be forced to raise capital through highly dilutive secondary equity offerings or convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry, permanently impairing per-share intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry for existing shareholders. |
| Clinical Trial Attrition Reality | Innovation And Product | -25% | -20% | Despite advanced computational vetting, biological systems remain highly complex and non-linear. The platform's outputs are still subject to the same unpredictable, binary in-human clinical trial failures as traditional biotechnology firms, as demonstrated by historical program terminations, which threatens to invalidate the core technology narrative. |
| Persistent Insider Liquidationinsider liquidationLarge-scale selling of an ownership position by founders, executives, or other major insiders.View full glossary entry | Management And Governance | -15% | -0.0% | Continuous, high-volume stock sales by executive leadership and founders under pre-arranged plans create a negative governance signal. This persistent insider selling undermines the public narrative of long-term platform compounding and clinical conviction, dampening institutional and retail investor sentiment. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Broad Clinical Pipeline Failure | 35% | -60% | Innovation And Product | Simultaneous or sequential failures of lead clinical assets due to lack of efficacy or unforeseen toxicity would shatter the core thesis that artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry improves drug discovery success rates. This would trigger a catastrophic loss of institutional confidence and partner flight. |
| Toxic Financing Death Spiraldeath spiralA self-reinforcing deterioration in which weakening fundamentals trigger actions that cause further decline.View full glossary entry | 30% | -50% | Capital Allocation | If capital markets remain frozen and partnership milestones stall, the company could hit a liquidity wall. Forced to raise capital under distressed conditions, management might execute highly dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry offerings or toxic debt structures, permanently destroying shareholder value. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Resounding Phase 2 Clinical Validation | 35% | +80% | Innovation And Product | A statistically undeniable efficacy and safety readout in a lead clinical trial would definitively prove that the platform's computational models translate into human biological success. This breakthrough would instantly de-risk the entire pipeline, trigger massive milestone payments, and spark a violent short squeezeshort squeezeA rapid increase in stock price caused by forced buying from short sellers covering their positions.View full glossary entry. |
| Hyperscaler Platform Acquisition | 20% | +100% | Competitive Positioning | A major technology giant or cash-rich pharmaceutical incumbent could acquire the company outright to secure its massive proprietary biological dataset and automated wet-lab infrastructure. This buyout would eliminate cash-burn concerns and deliver a substantial premium to public equity holders. |
Company Financial Analysis
Recursion Pharmaceuticals Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company's financial reports show a classic high-risk, high-reward profile. On one hand, revenue is growing, but it is highly unpredictable because it depends on lumpy milestone payments from big pharmaceutical partners rather than steady, recurring sales. On the other hand, the company is losing massive amounts of money, with annual losses and cash spending running into hundreds of millions of dollars. Financial experts agree that this level of cash burn is highly dangerous, especially in today's high-interest-rate environment where borrowing or raising money is very expensive. While some believe that future licensing deals will eventually bring in highly profitable revenue, others warn that the company is a melting ice cube that will continue to lose money for the foreseeable future. Investors must accept that the company is structurally unprofitable today and relies entirely on outside funding to survive.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 74.7M | USD -644.8M | USD -378.3M |
| 2024 | USD 58.8M | USD -463.7M | USD -372.9M |
| 2023 | USD 43.9M | USD -328.1M | USD -300.3M |
| 2022 | USD 39.7M | USD -239.4M | USD -120.9M |
| 2021 | USD 10M | USD -178.1M | USD -198.4M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company's current profit margins are deeply negative and structurally broken, as it spends far more on research and supercomputing than it makes in revenue. Traditional financial metrics like price-to-earnings ratios are completely useless here, as the company is priced entirely on its future potential rather than current profits. There is a sharp disagreement on when, or if, these margins will ever turn positive. Bullish outlooks suggest that if the company's operating system becomes the industry standard, profit margins will eventually explode to highly profitable, software-like levels. Bearish views, however, emphasize that the company is stuck in a high-cost model, burdened by the expensive physical realities of running clinical trials and maintaining hardware. Until the company can secure a massive, high-margin licensing deal that does not require expensive physical research, its margins will remain deeply in the red.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -648.1M | -867.9% | -863.4% |
| 2024 | USD -479M | -814.1% | -788.0% |
| 2023 | USD -350.1M | -797.8% | -747.7% |
| 2022 | USD -245.7M | -619.3% | -603.4% |
| 2021 | USD -182.8M | -1827.8% | -1780.7% |
Balance sheet and leverage
At first glance, the company's balance sheet looks incredibly strong and safe. It holds a large amount of cash and has almost no traditional debt, which normally suggests a very safe financial position. However, financial experts agree that this safety is a temporary illusion. Because the company is spending cash at an extremely rapid rate, its large cash reserve is actually a ticking clock. Most assessments agree that the current cash will only last for another two to three years before the company runs out of money. In today's tough financial climate, raising new money will be very difficult and will likely force the company to issue new shares at a low price, which would hurt existing investors. While the clean balance sheet provides some short-term safety, the company's long-term survival depends entirely on securing new cash from partners before its runway ends.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 78M | USD 743.3M | USD 665.3M net cash | 5.50x |
| 2024 | USD 108.5M | USD 594.4M | USD 485.9M net cash | 3.81x |
| 2023 | USD 50.7M | USD 391.6M | USD 340.9M net cash | 4.70x |
| 2022 | USD 51M | USD 549.9M | USD 498.9M net cash | 5.68x |
| 2021 | USD 11.5M | USD 516.6M | USD 273.6M net cash | 11.46x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company is spending heavily on its future, pouring massive amounts of capital into building advanced supercomputers and automated robotic laboratories. This heavy spending is designed to create a massive data advantage that competitors cannot easily copy. However, opinions are split on whether this intense investment is a smart move. Optimists view this spending as a necessary step to build an unbeatable moat that will eventually pay off through high-margin licensing deals. Skeptics, however, warn that the technology is depreciating rapidly, meaning the company must constantly spend more money just to keep its computers up to date. Furthermore, because drug development takes many years, the payback on this heavy spending is highly uncertain. If these expensive computers do not quickly lead to successful drugs, this massive spending could turn out to be a major waste of shareholder capital.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 6.5M | USD 425.3M |
| 2024 | USD 13.7M | USD 314.4M |
| 2023 | USD 12M | USD 241.2M |
| 2022 | USD 37.4M | USD 155.7M |
| 2021 | USD 39.8M | USD 135.3M |
Quarterly Forecast Scenarios
Recursion Pharmaceuticals Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $3.23 | $3.6068 | $4.37 | $736.09 | |
| $2.907 | $3.4871 | $4.1496 | $724.14 | |
| $2.1803 | $3.5694 | $4.5667 | $713.57 | |
| $1.9622 | $3.5842 | $5.6045 | $723.38 | |
| $1.8641 | $3.6409 | $5.0441 | $716.61 | |
| $1.7709 | $3.7208 | $5.8007 | $738.34 | |
| $1.948 | $3.9292 | $6.4968 | $746.91 | |
| $1.7532 | $4.2259 | $9.0955 | $771.93 | |
| $1.6655 | $4.4944 | $9.5502 | $782.73 | |
| $1.7488 | $4.79 | $11.46 | $807.31 | |
| $1.5739 | $5.2335 | $12.84 | $822.72 | |
| $1.4952 | $5.5006 | $15.15 | $846.10 | |
| $1.4952 | $5.5884 | $13.93 | $852.53 | |
| $1.57 | $6.0332 | $16.02 | $882.91 | |
| $1.4915 | $6.3862 | $20.03 | $900.46 | |
| $1.4779 | $6.8571 | $22.03 | $922.67 | |
| $1.3597 | $7.4793 | $25.34 | $935.91 | |
| $1.2917 | $7.9808 | $28.38 | $952.30 | |
| $1.2271 | $8.5696 | $30.65 | $976.28 | |
| $1.1044 | $9.082 | $33.71 | $1,002 |
Research Provenance
References & Context
This Recursion Pharmaceuticals consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).